Image Source: RSRT, Randol Family
VivoSense announces a series of new collaborations with the Rett Syndrome Research Trust (RSRT) to develop digital biomarkers that better assess the symptoms of Rett syndrome, focusing on autonomic dysfunction and other difficult-to-evaluate symptoms. The goal in developing these digital biomarkers is to better quantify and understand symptom impact on everyday life and to assess new treatments accurately.
The new collaboration partners with RSRT to analyze comprehensive physiologic data directly from patients using a variety of revolutionary biosensors, including MC10 Inc.’s BioStamp nPoint, an enterprise-class clinical research system. In this RSRT study, VivoSense will clean, analyze and label patient nPoint biopotential, accelerometry and gyroscopy data identifying abnormal breathing episodes associated with Rett Syndrome.
Recent scientific advances in rare diseases have fueled an interest in pursuing a portfolio of new drug and therapeutic approaches. Several drug candidates in rare disease indications, including Rett, have now reached open label. Gene therapy trials are on the horizon for several rare diseases.
VivoSense, in partnership with RSRT, will continue to develop novel digital biomarkers to improve treatments and outcomes for patients and caregivers living with Rett syndrome. VivoSense CEO, Dudley Tabakin, added, “VivoSense® software and specialized data analysts have been instrumental in developing novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials. We are excited to work with RSRT on developing further novel digital biomarkers for Rett Syndrome.”
VivoSense (Newport Coast, CA) is a digital biomarker discovery company providing data analysis for wearable sensors in regulated clinical trials. Having built an unparalleled validation and publications record in academic and healthcare research, VivoSense is now the leading company in sensor consulting and deployment of wearables with success in delivering biomarkers, which have led to drug approvals in international studies.
About the Rett Syndrome Research Trust
RSRT (Trumbull, CT) was launched in 2008 with a singular goal: to drive the development of treatments and cures for Rett Syndrome and related MECP2 disorders. To date, RSRT has funded over $66 million in academic and industry research. Recent industry partnerships focus on the development of therapeutics targeting the underlying cause of Rett Syndrome, the MECP2 gene.
Rett Syndrome is a neurological disorder resulting from a spontaneous genetic mutation affecting girls at an incidence of approximately 1 in 10,000 female births. Although rare, it is also possible for Rett Syndrome to affect males. After a period of normal development through ages 6 to 18 months, Rett patients develop a spectrum of symptoms, including loss of speech, stereotypic hand movements, cardio-respiratory dysfunction, difficulty coordinating movement, and increased risk of seizures. Currently, no cure for Rett Syndrome exists.
MC10, Inc. (Lexington, MA) is a privately held company focused on improving human health through digital solutions. They combine conformal BioStamp sensors with proprietary clinical analytics to unlock novel, actionable insights through physiological data collected from the home or in clinical settings. Their flagship product, BioStamp nPoint, is FDA-cleared and marketed to the clinical research community. For more about MC10, visit www.mc10inc.com or follow them on LinkedIn.